These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12621015)

  • 1. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
    Koral KF; Dewaraja Y; Li J; Lin Q; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
    J Nucl Med; 2003 Mar; 44(3):457-64. PubMed ID: 12621015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
    Koral KF; Dewaraja Y; Li J; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
    J Nucl Med; 2000 Sep; 41(9):1579-86. PubMed ID: 10994741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method.
    Koral KF; Francis IR; Kroll S; Zasadny KR; Kaminski MS; Wahl RL
    Cancer; 2002 Feb; 94(4 Suppl):1258-63. PubMed ID: 11877754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report.
    Koral KF; Dewaraja Y; Clarke LA; Li J; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
    Cancer Biother Radiopharm; 2000 Aug; 15(4):347-55. PubMed ID: 11041019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients.
    Koral KF; Zasadny KR; Kessler ML; Luo JQ; Buchbinder SF; Kaminski MS; Francis I; Wahl RL
    J Nucl Med; 1994 Oct; 35(10):1714-20. PubMed ID: 7931676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.
    Siegel JA; Kroll S; Regan D; Kaminski MS; Wahl RL
    J Nucl Med; 2002 Mar; 43(3):354-63. PubMed ID: 11884495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. I-131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusion of tracer images to computed tomography images.
    Koral KF; Li J; Dewaraja Y; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3004s-3009s. PubMed ID: 10541335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
    Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
    J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.
    Dewaraja YK; Schipper MJ; Shen J; Smith LB; Murgic J; Savas H; Youssef E; Regan D; Wilderman SJ; Roberson PL; Kaminski MS; Avram AM
    J Nucl Med; 2014 Jul; 55(7):1047-53. PubMed ID: 24842891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab.
    Wahl RL
    Semin Oncol; 2003 Apr; 30(2 Suppl 4):31-8. PubMed ID: 12728405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of 131I-tositumomab.
    Lewington V
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
    Song H; Du Y; Sgouros G; Prideaux A; Frey E; Wahl RL
    J Nucl Med; 2007 Jan; 48(1):150-7. PubMed ID: 17204712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in (131)I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma.
    Boucek JA; Turner JH
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):458-69. PubMed ID: 15821965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The radioisotope contributes significantly to the activity of radioimmunotherapy.
    Davis TA; Kaminski MS; Leonard JP; Hsu FJ; Wilkinson M; Zelenetz A; Wahl RL; Kroll S; Coleman M; Goris M; Levy R; Knox SJ
    Clin Cancer Res; 2004 Dec; 10(23):7792-8. PubMed ID: 15585610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
    Mones JV; Coleman M; Kostakoglu L; Furman RR; Chadburn A; Shore TB; Muss D; Stewart P; Kroll S; Vallabhajosula S; Goldsmith SJ; Leonard JP
    Leuk Lymphoma; 2007 Feb; 48(2):342-8. PubMed ID: 17325895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.
    Wahl RL; Zasadny KR; MacFarlane D; Francis IR; Ross CW; Estes J; Fisher S; Regan D; Kroll S; Kaminski MS
    J Nucl Med; 1998 Aug; 39(8 Suppl):21S-27S. PubMed ID: 9708567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
    Kaminski MS; Radford JA; Gregory SA; Leonard JP; Knox SJ; Kroll S; Wahl RL
    J Clin Oncol; 2005 Nov; 23(31):7985-93. PubMed ID: 16204016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
    J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
    Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW
    J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.